Publication:
Developing the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire

dc.contributor.authorPraveena Chiowchanwisawakiten_US
dc.contributor.authorLuksame Wattanamongkolsilen_US
dc.contributor.authorVaralak Srinonpraserten_US
dc.contributor.authorChonachan Petcharaten_US
dc.contributor.authorPalanan Siriwanarangsunen_US
dc.contributor.authorWanruchada Katchamarten_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-11T02:57:24Z
dc.date.accessioned2019-03-14T08:01:39Z
dc.date.available2018-12-11T02:57:24Z
dc.date.available2019-03-14T08:01:39Z
dc.date.issued2016-10-01en_US
dc.description.abstract© 2016, Springer-Verlag Berlin Heidelberg. To validate the Thai language version of the Psoriasis Epidemiology Screening Tool (PEST) and the Early Arthritis for Psoriatic Patients Questionnaire (EARP), as well as also to develop a new tool for screening psoriatic arthritis (PsA) among psoriasis (Ps) patients. This was a cross-sectional study. Ps patients visiting the psoriasis clinic at Siriraj Hospital were recruited. They completed the EARP and PEST. Full musculoskeletal history, examination, and radiography were evaluated. PsA was diagnosed by a rheumatologist’s evaluation and fulfillment of the classification criteria for psoriatic arthritis. Receiver operator characteristic (ROC) curves, sensitivity, and specificity were used to evaluate the performances of the tools. The Siriraj Psoriatic Arthritis Screening Tool (SiPAT) contained questions most relevant to peripheral arthritis, axial inflammation, and enthesitis, selected from multivariate analysis. Of a total of 159 patients, the prevalence of PsA was 78.6 %. The ROC curve analyses of Thai EARP, PEST, and SiPAT were 0.90 (95 % CI 0.84, 0.96), 0.85 (0.78, 0.92), and 0.89 (0.83, 0.95), respectively. The sensitivities of SiPAT, Thai EARP, and PEST were 91.0, 83.0, and 72.0 %, respectively, while the specificities were 69.0, 79.3, and 89.7 %, respectively. All screening questionnaires showed good diagnostic performances. SiPAT could be considered as a screening tool with its desirable properties: higher sensitivity and taking less time. Thai PEST and EARP could possibly be sequentially administered for people with a positive test from SiPAT to reduce the number of false positives.en_US
dc.identifier.citationRheumatology International. Vol.36, No.10 (2016), 1459-1468en_US
dc.identifier.doi10.1007/s00296-016-3513-4en_US
dc.identifier.issn1437160Xen_US
dc.identifier.issn01728172en_US
dc.identifier.other2-s2.0-84975513294en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/40749
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84975513294&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleDeveloping the Thai Siriraj Psoriatic Arthritis Screening Tool and validating the Thai Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaireen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84975513294&origin=inwarden_US

Files

Collections